(Q37983791)

26 August 2017

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management (English)

1 reference

26 August 2017

0 references

1 reference

1

Ayalew Tefferi

1 reference

26 August 2017

1 March 2012

1 reference

American Journal of Hematology

26 August 2017

1 reference

26 August 2017

87

1 reference

26 August 2017

3

1 reference

26 August 2017

285-293

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

26 August 2017

1 reference

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

The JAK2 exon 12 mutations: a comprehensive review

21 January 2018

1 reference

Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis.

21 January 2018

1 reference

Two rare MPL gene mutations in patients with essential thrombocythemia.

21 January 2018

1 reference

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia

21 January 2018

1 reference

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

21 January 2018

1 reference

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

21 January 2018

1 reference

MPLW515L mutation in acute megakaryoblastic leukaemia.

21 January 2018

1 reference

Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation.

21 January 2018

1 reference

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

21 January 2018

1 reference

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

21 January 2018

1 reference

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

21 January 2018

1 reference

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients

21 January 2018

1 reference

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.

21 January 2018

1 reference

Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.

21 January 2018

1 reference

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

21 January 2018

1 reference

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia

21 January 2018

1 reference

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia

21 January 2018

1 reference

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

21 January 2018

1 reference

The haematocrit and platelet target in polycythemia vera

21 January 2018

1 reference

Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations

21 January 2018

1 reference

Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies

21 January 2018

1 reference

Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies

21 January 2018

1 reference

A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs.

21 January 2018

1 reference

Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.

21 January 2018

1 reference

Pruritus in polycythaemia vera: prevalence, laboratory correlates and management

21 January 2018

1 reference

The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

21 January 2018

1 reference

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

21 January 2018

1 reference

Pregnancy in essential thrombocythaemia: experience with 40 pregnancies

21 January 2018

1 reference

A single institutional experience with 43 pregnancies in essential thrombocythemia

21 January 2018

1 reference

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

21 January 2018

1 reference

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe

21 January 2018

1 reference

Thrombocythaemia and pregnancy

21 January 2018

1 reference

Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus

21 January 2018

1 reference

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera.

21 January 2018

1 reference

The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation

21 January 2018

1 reference

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

21 January 2018

1 reference

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management

21 January 2018

1 reference

Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alpha-adrenergic receptors

21 January 2018

1 reference

Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera

21 January 2018

1 reference

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

21 January 2018

1 reference

Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

21 January 2018

1 reference

A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP)

21 January 2018

1 reference

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

21 January 2018

1 reference

Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution

21 January 2018

1 reference

Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

21 January 2018

1 reference

Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre

21 January 2018

1 reference

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 January 2018

1 reference

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

21 January 2018

1 reference

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23135

1 reference

26 August 2017

1 reference

PubMed ID

22331582